Apatinib is a novel small-molecule oral tyrosine kinase inhibitor that selectively binds VEGFR-2, thus decreasing VEGF-mediated endothelial cell migration, proliferation, and tumor microvessel density12. The gene discussed is KDR; the disease is neoplasm.